Clinical Trial Update: A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial comparing relatlimab plus nivolumab versus nivolumab alone in advanced melanoma has results posted, with the study currently active but not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-03-29